LTC Properties vs Sabra Health Care REIT
LTC and SBRA side by side, both in miscellaneous investing. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LTC and SBRA compare
Sabra Health Care REIT is the larger company, worth 2.1 times as much as LTC Properties ($5.0B against $2.4B).
On earnings, LTC Properties is cheaper: it trades at 16.4× trailing earnings, against 75.9× for Sabra Health Care REIT.
LTC Properties grew revenue faster over the last twelve months (59.8% versus 17.3% for Sabra Health Care REIT).
LTC Properties keeps more of each dollar of sales as profit, with a net margin of 38.9% compared with 7.6% at Sabra Health Care REIT.
Both pay dividends: LTC Properties yields 4.7% and Sabra Health Care REIT 6.1%.
LTC Properties scores higher on the StockData Score (19 against 7 for Sabra Health Care REIT), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LTC | SBRA |
|---|---|---|
| Size and price | ||
| Market cap | $2.4B | $5.0B |
| Share price | $44.75 | $19.74 |
| Change, 1 year | 29.2% | 14.6% |
| Change, 5 years | 32.3% | 32.2% |
| Beta (5Y) | 0.42 | 0.48 |
| Employees | 25 | 58 |
| StockData Score | ||
| Total score | 19 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 4 (better) | 2 |
| Health score | 4 (better) | 0 |
| Dividend score | 5 (better) | 3 |
| Valuation | ||
| P/E | 16.4× (better) | 75.9× |
| P/S | 6.9× | 5.9× (better) |
| P/B | 1.9× | 1.8× (better) |
| EV/EBITDA | 9.3× (better) | 12.5× |
| PEG | 30.65 | – |
| Fair value | $46.81 | $12.68 |
| Margin of safety | 4.4% (better) | −55.7% |
| Growth | ||
| Revenue growth (TTM) | 59.8% (better) | 17.3% |
| Revenue growth, 5Y average | 10.5% (better) | 5.3% |
| Net income growth (TTM) | 62.7% (better) | −64.1% |
| EPS growth (TTM) | 50.0% (better) | −65.8% |
| EPS growth, 5Y average | 0.81% (better) | −0.91% |
| Profitability | ||
| Operating margin | 62.6% | – |
| Net margin | 38.9% (better) | 7.6% |
| Return on equity | 12.2% (better) | 2.4% |
| Return on invested capital | 19.8% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Altman Z-score | 2.22 (better) | 1.25 |
| Piotroski F-score | 6 | 6 |
| Dividends and buybacks | ||
| Dividend yield | 4.7% | 6.1% (better) |
| Payout ratio | 83.3% | 455% |
| Years of dividend growth | 0 | 0 |
| Dividend growth, 5Y average | 0.00% (better) | −2.3% |
| Buyback yield | −11.8% | – |
| Shareholder yield | −7.1% | 6.1% (better) |
| Ownership | ||
| Held by institutions | 79.7% | 102% |
| Held by insiders | 2.2% | 1.9% |
| Insider net buying, 12 months | $1.3M (better) | −$4.5M |
| Short interest, % of float | 6.2% | 7.9% |
Go deeper
- LTC stock overview
- LTC income statement
- LTC valuation and score
- SBRA stock overview
- SBRA income statement
- SBRA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.